Financial health
- Operating income covered interest expense -3392.1× in the latest year, down from -292.5× 5 years ago.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$117M | — | — | -$97M | — | $39M |
| 2024 | — | -$117M | — | — | -$93M | — | $56M |
| 2023 | — | -$143M | — | — | -$98M | — | $160M |
| 2022 | — | -$70M | — | — | -$62M | — | $258M |
| 2021 | — | -$62M | — | — | -$64M | — | $278M |
| 2020 | — | -$37M | — | — | -$43M | — | $84M |
| 2019 | — | -$28M | — | — | -$29M | — | $11M |
| 2018 | — | -$9M | — | — | -$19M | — | $9M |
| 2017 | — | -$34M | — | — | -$11M | — | $53M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$20M | — | — | -$22M | — | $36M |
| Dec '25 | — | -$31M | — | — | -$21M | — | $39M |
| Sep '25 | — | -$27M | — | — | -$23M | — | $29M |
| Jun '25 | — | -$31M | — | — | -$27M | — | $35M |
| Mar '25 | — | -$28M | — | — | -$27M | — | $28M |
| Dec '24 | — | -$29M | — | — | -$24M | — | $56M |
| Sep '24 | — | -$30M | — | — | -$22M | — | $105M |
| Jun '24 | — | -$30M | — | — | -$24M | — | $224M |
| Mar '24 | — | -$28M | — | — | -$23M | — | $160M |
| Dec '23 | — | -$29M | — | — | -$24M | — | $160M |
| Sep '23 | — | -$50M | — | — | -$22M | — | $183M |
| Jun '23 | — | -$32M | — | — | -$26M | — | $205M |
| Mar '23 | — | -$31M | — | — | -$26M | — | $232M |
| Dec '22 | — | $45M | — | — | -$25M | — | $258M |
| Sep '22 | — | -$22M | — | — | -$20M | — | $283M |
| Jun '22 | — | -$23M | — | — | -$18M | — | $261M |
| Mar '22 | — | $5M | — | — | $1M | — | $278M |
| Dec '21 | — | -$16M | — | — | -$17M | — | $278M |
| Sep '21 | — | -$14M | — | — | -$17M | — | $192M |
| Jun '21 | — | -$11M | — | — | -$15M | — | $209M |
See the revenue and net-income charts above for Adicet Bio, Inc.'s multi-year trend.
As of FY2025, Adicet Bio, Inc. reported — of total debt against $39M of cash; operating income covered interest expense -3392.1×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.